Clinical Edge Journal Scan

Comorbidities account for an increased risk for VTE in PsA


 

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Recommended Reading

More frequent secukinumab dosing found to benefit overweight psoriasis patients
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: PsA February 2022
MDedge Rheumatology
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
MDedge Rheumatology
How to make the most of your time with psoriasis patients
MDedge Rheumatology
Guselkumab controls axial involvement in PsA through 2 years
MDedge Rheumatology
Dietary recommendations for inflammatory rheumatic diseases
MDedge Rheumatology
Patients are interrupting DMARD use well into the COVID-19 pandemic
MDedge Rheumatology
PsA: Secukinumab provides early and clinically meaningful improvements in patient-reported outcomes
MDedge Rheumatology
Psoriasis with concomitant psoriatic arthritis tied to an increased risk for endometriosis
MDedge Rheumatology
Predicting the risk for uveitis in juveniles with PsA
MDedge Rheumatology